Clinical trials
Chronic Liver Disease and Cirrhosis clinical trials
Below are recruiting chronic liver disease and cirrhosis clinical trials, each written for real people, not researchers. We’re tracking 196 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT00345930Recruiting
Study of liver injury after medicines or supplements
This study looks at people (including children over age 2) who develop liver injury that may be caused by a drug or a complementary/alternative medicine (CAM) product. It helps doctors better understand what causes the injury and how to evaluate it.
Los Angeles, CaliforniaAges 2 years+ - NCT04442334Recruiting
European registry for people with fatty liver
This registry collects health and lifestyle information from adults with suspected or confirmed fatty liver (NAFLD) to help researchers better understand the condition. You may be asked about diet, exercise, alcohol intake, and some liver-related tests.
AntwerpAges 18–100 - NCT03929900Recruiting
Study follow-up for kidney disease in adults (non-dialysis)
This study follows adults with chronic kidney disease who are not on dialysis. It aims to better understand kidney health and test what care or monitoring might help over time.
Seoul, Jongno-guAges 45–79 - NCT05541601Recruiting
Study to detect liver cancer early in people with cirrhosis
This study follows people with cirrhosis to see how best to detect liver cancer early. If you qualify, you may receive regular monitoring that could help find liver cancer sooner, when treatment is more likely to work.
Oxford, OxfordshireAges 18–100 - NCT07804316Recruiting
Food choice app for chronic kidney disease patients
This study tests a mobile app that helps people with chronic kidney disease (CKD) make healthier food choices. It aims to empower you to manage your condition better through daily food tracking and personalized guidance.
SingaporeAges 21 years+ - NCT07496177RecruitingPhase 2
HTD1801 for kidney function in diabetes and kidney disease
This trial tests whether a new drug, HTD1801, can protect or improve kidney function in people with type 2 diabetes and chronic kidney disease. It may help slow kidney damage and reduce protein in urine.
Weifang, ShandongAges 18–75 - NCT05014178Recruiting
Kidney salt imaging scan with MRI
This study uses an MRI scan to look at how your kidneys handle salt (sodium). It may help researchers better understand kidney function in healthy people and in people with chronic kidney disease.
London, OntarioAges 18 years+ - NCT07333313Recruiting
Study of oral medicine and probiotics for kidney disease in diabetes
This trial tests if an oral medication that absorbs toxins plus probiotics can reduce inflammation and slow kidney damage in people with diabetes-related kidney disease (DKD). It may help those with mild to severe kidney function loss.
Taipei, TaiwanAges 20 years+ - NCT06913647RecruitingPhase 2
Canagliflozin for fluid removal and health in peritoneal dialysis patients
This trial tests if canagliflozin, a diabetes medicine, helps remove extra fluid and reduce scarring in people on peritoneal dialysis (home-based dialysis). It may improve your dialysis results and protect your belly lining.
Montreal, QuebecAges 18 years+ - NCT06801886Enrolling by invitationPhase 3
Silymarin for better kidney transplant success
This trial tests if adding silymarin (a milk thistle extract) to standard anti-rejection medicines helps protect the new kidney from damage. It may improve how well the transplanted kidney works over time.
MartinAges Any age - NCT04819217Recruiting
Probiotics and a toxin binder to slow chronic kidney disease
This trial studies an oral product (a “uremic toxin” absorber) plus probiotics to help slow the progression of chronic kidney disease. It may help by lowering harmful gut-related substances that can build up when kidney function is reduced.
TaipeiAges 20 years+ - NCT05028829RecruitingPhase 2
Atorvastatin to lower liver cancer risk in people with liver scarring
This trial tests whether atorvastatin (a cholesterol medicine) can lower the chance of liver cancer (HCC) in people with advanced liver scarring or cirrhosis. Participants are compared to placebo (inactive pill) while researchers track safety and cancer risk.
Boston, MassachusettsAges 18 years+ - NCT04036357Recruiting
Study of liver fat disease with heart and metabolism problems
This study looks at people with fatty liver disease and common health issues like obesity, diabetes, high blood pressure, or abnormal cholesterol. It may help researchers understand how liver fat and heart/metabolism problems relate and how they affect health over time.
RomeAges 18–80 - NCT07441226RecruitingPhase 2
Stem cells for advanced COPD treatment
This trial tests whether adding umbilical cord stem cells to standard triple therapy can help people with Group E COPD. It aims to see if this approach improves lung function and quality of life.
Jakarta, Jakarta Special Capital RegionAges 40–75 - NCT07335042Recruiting
Heart injury risk after major liver or bile duct surgery
This study looks at whether certain patients have heart muscle injury (called MINS) after major liver or bile duct surgery. If you are having this type of surgery, your doctors will check your heart with a special blood test before and after. The goal is to find out who is at risk and help prevent problems.
BeijingAges 18–85 - NCT07133880RecruitingPhase 4
Nebulizer vs inhaler for COPD breathing treatment
This study compares two ways to deliver long-acting bronchodilator medications for COPD: a nebulizer (machine that turns liquid medicine into a mist) versus a handheld inhaler. The goal is to see which method works better for people with moderate to severe COPD symptoms.
Knoxville, TennesseeAges 40 years+ - NCT06976762Enrolling by invitation
Light-based muscle oxygen measurements in COPD with kidney disease
This study uses a special light-based device (near-infrared spectroscopy) to measure muscle oxygen levels in people who have both COPD and chronic kidney disease. Researchers want to see if these measurements can help predict how the disease progresses, which could lead to better monitoring and treatment.
Tokat ProvinceAges 18–80 - NCT06820749Enrolling by invitationPhase 2
Study of HSK31858 tablets for lung mucus conditions
This trial tests an investigational tablet for people with chronic lung diseases like bronchiectasis, COPD, or asthma who produce at least 10 mL of sputum (mucus coughed up from the lungs) each day. The goal is to see if the drug safely reduces excess airway mucus.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06121492Enrolling by invitationPhase 3
Amino Acid Drink for Muscle Loss in Liver Cirrhosis
This study tests whether taking a daily drink of branched-chain amino acids (a type of protein) can help people with liver cirrhosis who have lost muscle strength and mass. It may help improve muscle size and function.
Bangkok, BangkokAges 18–85 - NCT04722835Recruiting
Study lung immune cells in people at risk for COPD
This study looks at different lung immune cell patterns and how they work in smokers who are not yet diagnosed with COPD or asthma. It may help researchers understand why some people are more likely to develop COPD, which could guide future prevention or early treatments.
San Francisco, CaliforniaAges 40–75 - NCT07554183Recruiting
Using MRI to study blood flow before TIPS in cirrhosis
This study uses an advanced MRI technique (called 4D-flow) to look at blood flow in the liver before and after a TIPS procedure (a small tube that helps lower blood pressure in the liver). The goal is to better understand how TIPS affects blood flow and outcomes, which may help improve care for people with cirrhosis.
ParisAges 18 years+ - NCT06217302RecruitingPhase 3
Sotagliflozin for kidney protection in type 1 diabetes
This study tests whether sotagliflozin (a pill that helps control blood sugar and protects the kidneys) can slow down kidney function decline in people with type 1 diabetes and diabetic kidney disease. You may qualify if you have had type 1 diabetes for at least 8 years, have moderate kidney damage, and are on standard treatments.
Stanford, CaliforniaAges 18–75 - NCT06874127Recruiting
Predicting liver repair in hepatitis B after treatment
This study looks at whether non-invasive tests can tell if liver damage is reversing in people with hepatitis B who have been on antiviral therapy for at least a year. It aims to help avoid repeated liver biopsies.
BeijingAges 18 years+ - NCT06832189RecruitingPhase 1
Testing everolimus and epoetin for liver transplant tolerance
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
San Francisco, CaliforniaAges 18 years+
Hear when a new Chronic Liver Disease and Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic liver disease and cirrhosis?
- Yes. Clin2 currently lists 196 recruiting chronic liver disease and cirrhosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic liver disease and cirrhosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic liver disease and cirrhosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.